PDCD1 and neoplasm: PD-L1, recognized as a key and logical immune biomarker for PD-1/PD-L1 checkpoint blockade therapy, was notably linked with treatment outcomes in immune and tumor cells, as demonstrated in studies such as IMvigor 210 and Checkmate 275 [37, 38].